The Underrecognized Toll of Prescription Opioid Abuse on Young Children

      Study objective

      The impact of prescription opioid abuse on young children is underrecognized and poorly documented. We hypothesize that poisoning of young children from prescription opioids occurs regularly in the United States and is associated with serious health events, including death.


      Using data from poison centers participating in the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System, exposures in children younger than 6 years, involving buprenorphine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, and oxycodone (January 2003 to June 2006), were quantified and described.


      We identified 9,179 children exposed to a prescription opioid. The median age was 2.0 years (range newborn to 5.5 years), and 54% were boys. Nearly all exposures involved ingestion (99%) and occurred in the home (92%). Exposures to any opioid were associated with 8 deaths, 43 major effects, and 214 moderate effects. Of 51 patients who experienced a major effect or death, 35 were treated with naloxone: a beneficial response was documented in 34 patients. All 5 exposures to buprenorphine associated with a major effect were treated with naloxone, and a beneficial response was recorded in all 5. Nearly all exposures were to medications prescribed for adults in the household. The number of prescriptions filled for an opioid in an area correlated well with exposures in young children in the same area; children have access to household members' prescription drugs.


      Young children are exposed to prescription opioids, typically prescribed for other patients, resulting in major health effects and death.
      To read this article in full you will need to make a payment
      ACEP Member Login
      ACEP Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Department of Health and Human Services Substance Abuse and Mental Health Administration
        Results from the 2005 National Survey on Drug Use and Health: national findings.
        (Accessed April 10, 2007)
        • Paulozzi L.J.
        • Budnitz D.S.
        • Xi Y.
        Increasing deaths from opioid analgesics in the United States.
        Pharmacoepidemiol Drug Safety. 2006; 15: 618-627
        • Geib A.J.
        • Babu K.
        • Ewald M.B.
        • et al.
        Adverse effects in children after unintentional buprenorphine exposure.
        Pediatrics. 2006; 118: 1746-1751
        • Cicero T.J.
        • Dart R.C.
        • Inciardi J.A.
        • et al.
        The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®).
        Pain Med. 2007; 8: 157-170
        • American Association of Poison Control Centers
        Instructions for the American Association of Poison Control Centers Toxic Exposure Surveillance System (2001).
        (Accessed July 5, 2007)
        • Bailey J.E.
        • Barton P.L.
        • Lezotte D.
        • et al.
        The effect of FDA approval of a generic competitor to OxyContin® (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
        Drug Alcohol Depend. 2006; 84: 182-187
        • Hughes A.H.
        • Bogdan G.M.
        • Dart R.C.
        Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison.
        Clin Toxicol. 2007; 45: 144-151
        • Smith M.Y.
        • Dart R.C.
        • Hughes A.A.
        • et al.
        Clinical validation of poison control center (PCC) intentional exposure cases involving prescription opioids.
        Am J Drug Alcohol Abuse. 2006; 32: 465-478
      1. Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) drug label.
        (Accessed August 1, 2008.)